

Empowering Data-Driven Health Care Decisions

Annual Report 2021-22

Empowering Data-Driven Health Care Decisions

Annual Report 2021-22



BioGrid Facts



42

Number of Members at 30 June 2022

representing
81 institutions



325

Journal publications
reported to date
that have utilised
BioGrid for their
research.



102

active research projects during 2021-22,
represented across all states and the ACT

Thirty-nine



Current Institution Ethics Approvals
at 30 June 2022

Contents

02

Members and Collaborators

04

Chair's Report

06

Chief Executive Officer's Report

08

About BioGrid

10

Operational Report

12

Projects

- APPRISE Virtual Biobank: Leveraging technology to maximise the value of human biospecimens
- National Inpatient Penicillin Allergy Database: improving hospital procedures and national policy on antibiotic prescribing
- Learning Health Systems (LHS) and informatics
- BREAST Registry - Real World Evidence to tackle breast cancer

16

Directors' Report

23

Financial Report

30

Directors' Declaration

Members and Collaborators

BioGrid Australia Ltd is a not for profit company limited by guarantee. Its members are health services, universities and research institutes. At the time of this report, BioGrid's overarching evergreen collaboration agreement has been executed with 42 institutions (representing 81 sites across Australia) covering the management of governance, intellectual property, data access, undertaking projects, commercialisation and publications.



ACT Health
Canberra Hospital

AlfredHealth

Alfred Health
The Alfred
Caulfield Hospital
Sandringham Hospital



Austin Health
Austin Hospital
Heidelberg Repatriation Hospital



Baker IDI Heart and Diabetes Institute



Ballarat Health Services
Ballarat Base Hospital
Queen Elizabeth Centre



Barwon Health
Geelong Hospital



Bendigo Health
Bendigo Hospital



Central Adelaide Local Health Network
Royal Adelaide Hospital
The Queen Elizabeth Hospital



Eastern Health
Angliss Hospital
Box Hill Hospital
Healesville Hospital
Maroondah Hospital



Fiona Stanley Hospital



Gold Coast Hospital and Health Service*
Gold Coast University Hospital
Robina Hospital



Goulburn Valley Health
Goulburn Valley Hospital



Hudson Institute of Medical Research



Latrobe Regional Hospital



La Trobe University*



Mater Health Service



Melbourne Health
The Royal Melbourne Hospital



Metro North Hospital and Health Service
Royal Brisbane and Women's Hospital
Prince Charles Hospital



Metro South Hospital and Health Service*
Princess Alexandra Hospital



Monash Health
Monash Medical Centre, Clayton
Monash Medical Centre, Moorabbin
Casey Hospital
Dandenong Hospital

* Non-Member Collaborator of BioGrid Australia



Monash University*



**Murdoch Childrens
Research Institute**



**Northern Adelaide
Local Health Network**

Lyell McEwin Hospital
Modbury Hospital



Northern Health
The Northern Hospital



Peninsula Health
Frankston Hospital
Rosebud Hospital



**Peter MacCallum
Cancer Centre**



**Radiation Oncology
Victoria**



**St Vincent's Hospital,
Melbourne**



**St Vincent's Hospital,
Sydney**



**St John of God
Health Care**

Ballarat, Bendigo, Berwick, Bunbury,
Burwood, Geelong, Geraldton, Midland,
Murdoch, Mt Lawley, Richmond,
Subiaco and Warrnambool Hospitals



**South Western Sydney
Local Health District**

Campbelltown Hospital
Liverpool Hospital
Bankstown Hospital



**Sydney Local
Health District**

Royal Prince Alfred, Concord
Repatriation General,
Balmain, Canterbury and
Sydney Dental Hospitals



**Tasmanian Government
Department of Health
and Human Services**

Royal Hobart Hospital
Launceston General Hospital



**The Royal
Children's Hospital**



**The Royal Women's
Hospital**



**The University of
New South Wales**



**The University of
Melbourne**



**The University of
Western Australia**



**The Walter and Eliza Hall
Institute of Medical
Research**



**Victorian Comprehensive
Cancer Centre**



Western Health

Western Health
Footscray Hospital
Sunshine Hospital
The Williamstown Hospital

West Moreton Health

**West Moreton Hospital
and Health Service**

Ipswich Hospital, Brisbane

* Non-Member Collaborator of BioGrid Australia

Chair's Report



The 2021-2022 financial year was one of continuing to build for BioGrid's future, and despite the challenging conditions of the past two years, I'm pleased to report that we are seeing positive results for the work done so far. A key driver for this work is BioGrid's growth strategy, released in 2021, which acknowledges where medical research is heading in Australia and overseas, recognises the current and likely new challenges for the sector, and clearly outlines what BioGrid needs to do to remain sustainable and relevant to the community we support.

BioGrid's strategic objectives are therefore to:

- Grow the business through innovation and customer advocacy
- Modernise our trusted infrastructure and data security processes
- Optimise and deepen customer data value
- Accelerate customer success through leveraging our collaboration enablers

During the 2021-22 financial year we've seen tangible progress on this strategy, which is reflected in our positive financial results this year. Turnover this year was a very healthy \$2.7 million, the result of the hard work by the BioGrid team to ensure our project pipeline was kept active while we waited to see how the COVID-19 pandemic would unfold.

A key component of BioGrid's Strategy is the enabling elements – a skilled talent pool of people; Board advocacy, skills and experience; state of the art systems, processes and practice; and then the tools, experience and governance for coordination, collation and curation of clinical datasets.

The controls on skilled migration during the COVID-19 pandemic and the resulting very high levels of employment have made resourcing of skilled staff particularly challenging in our niche area of operations. This has tempered our ability to grow at the level we'd prefer, but we anticipate that when restrictions on migration are relaxed we will be able to ensure that plank of the strategy is prioritised.

The entire health sector is still dealing with issues such as delayed contracting, which also impacted BioGrid. Despite this, the company continues to work on plans for a cloud-based Digital Research Environment, which is key to opening up BioGrid's services to a broader range of clients and more complex projects, both in Australia and internationally.



In the context of the challenges of the past year, my Board colleagues and I are pleased to see that BioGrid's profile continues to grow, and the disease areas represented by the company's program of work is expanding as researchers learn about BioGrid's capabilities.

The challenge for the company over the next year will be continuing to maintain an agile approach to growth and the development of business opportunities. BioGrid is uniquely positioned to address the challenges facing Australian researchers – a small population, located in dispersed locations, and a health system that is relatively unlinked, all making it extremely complex to study medical conditions in a meaningful and, importantly, cost-effective manner. I anticipate the next few years will be ones of rapid growth and I look forward to celebrating BioGrid's achievements.

Thank you to James Dromey, a long-term Director who stepped down from the BioGrid Board in June 2022. James chaired the Board's Business Development Subcommittee from its establishment in August 2018, guiding the company's business development work that aimed to build BioGrid's opportunities into the future by ensuring we were identifying and capitalising on those opportunities. James's contribution and passion for the work done by BioGrid is very much appreciated.

Thank you once again to BioGrid's CEO Maureen Turner for her tireless commitment, passion and long hours leading the BioGrid team. Her immense capability in business management, her vision for what BioGrid can be and her unflagging faith in the value of what BioGrid have kept BioGrid viable in a very difficult couple of years.

Thank you also to my fellow Board members for their tireless work on the BioGrid Strategy, setting up the company for future sustainability, and the BioGrid team themselves for their incredible effort in continuing to deliver a high-quality service during a very challenging time.

Rob Grenfell
Chair, BioGrid Australia

Chief Executive Officer's Report



The 2021-22 financial year has been one with many reasons to celebrate among the ongoing impacts of the COVID-19 pandemic. While BioGrid continues to experience delays relating to COVID-19 across our sector, we are already well on our way to achieving our forecast income for the 2022-23 financial year and the company's cash flow continues to be positive.

During this financial year we saw an expansion of the disease programs we're working with beyond Oncology, and our pipeline of work included new areas such as Cardiology, Neurology and Dermatology. This is a testament to the work we have done over the past two years on refining our business strategy and increasing our focus on business development.

However, our ability to service new areas relies on being able to recruit and retain highly trained and specialised staff, which is an ongoing challenge made more difficult during the pandemic when skilled migration was paused for a long period. With our strategic push to move to an agile research, cloud ready environment, we have had to prioritise retaining and recruiting staff to maintain our ability to both deliver our program of work and prepare for the future.

One of the key elements for our continued growth, identified in the BioGrid 2021-22 Strategy and associated Business Plan, is ensuring we engage regularly and deeply with clients and members to understand their needs, now and into the future. During the year we contracted a Communications Specialist to assist with articulating the BioGrid story and regularly sharing information about the work we are doing. Complementing this activity, we plan to appoint a Business Development Specialist in the 2022-23 financial year for a fixed term and will engage with our stakeholders to gather feedback that will inform our forward planning. BioGrid was established to work 'hand-in-glove' with our research partners, and it is essential that we are working together to ensure we can continue to support their evolving requirements.

While this work is proceeding, I am excited by the expansion we are seeing in the types of research programs we are supporting, even in the difficult context of the COVID-19 pandemic. An example of this was the delivery of phase 1 of the APPRISE Virtual Biobank, which will provide relatively high-level information about six Australian COVID-related specimen collections to researchers.



A significant achievement during 2021-22 was the commencement of the Data Connect program, a collaboration with the VCCC Alliance, the University of Melbourne and hospitals within the VCCC Alliance. Funded by the Victorian Government under the VCCC Alliance Research Strategy funding, Data Connect will link more than 130 million primary care and hospital medical records for the first time in Australia, enabling researchers to study the continuum of cancer care for patients.

I am also pleased to see that our work promoting our grant application assistance is gaining traction. Research data infrastructure is often overlooked during the grant application process, but it's a significant cost to a program and needs to be considered when a grant application is prepared. In 2021-22 we provided assistance during the grant-writing phase to eight projects that submitted applications for MRFF funding.

These projects included the National Cohort Data Platform (integrating five leading national and related cancer cohort data assets), Transformation of the National Antimicrobial Prescribing Service (NAPS), The Australian National Biobanking Registry (a national biobank and biospecimen registry), and a collaboration between Royal Melbourne Hospital, WEHI, BioGrid and CSL Ltd to develop the first Victorian Immune and Inflammatory Diseases BioBank (VIIDBioB).

Having the opportunity to provide advice to researchers seeking the grants about data collection tools, data linkage, data analysis and reporting at the front end of the grant process has been a positive approach, ensuring peace of mind that data tools and services are properly funded.

Going forward, a key lever for BioGrid's growth and sustainability will be the capacity to offer clients a cloud-based digital research environment (DRE). Work continues on the scoping of requirements for this and the identification of

potential providers with expertise in this area. A cloud-based DRE offers expanded opportunities for collaboration and gold standard security, enabling clients to collect, store and work with data in a single space.

While the past two years have been extremely challenging, I am very optimistic about the coming years for BioGrid, particularly given that we have continued to grow our business and implement a robust business strategy that supports sustainable growth. This is due in most part to the dedicated specialists that make up the BioGrid team, about whom I regularly receive overwhelmingly positive feedback. I am always impressed by their commitment to going above and beyond to help our members solve often complicated or unique data problems and ultimately deliver improved health outcomes to the Australian community.

The BioGrid Executive Team and I are also grateful for the support of our Board and Member Management Committees, who volunteer their time to ensure that BioGrid can continue to deliver excellent service to our stakeholders.

I look forward with anticipation to the coming years for BioGrid, as we move into a more positive period of achievement and growth.

Maureen Turner
CEO, BioGrid Australia


About BioGrid


Data governance, security and ethics are at the core of BioGrid's federated data sharing platform that securely links patient level clinical, biospecimen, genetic and imaging data sets across multiple sites and diseases for the purpose of medical research.

BioGrid's infrastructure and data management strategies address the increasing need by authorised researchers to dynamically extract and analyse data from multiple sources whilst protecting patient privacy.

In the health sector, BioGrid is a trusted independent virtual real-time data repository. Investment in BioGrid has facilitated a combination of technology, collaboration and ethics approval processes for data sharing that exist nowhere else in the world.

For more information on how BioGrid works, what data is linked to BioGrid and how to access data, go to www.biogrid.org.au.





1. Patient information is recorded in one or more data sources (i.e. databases, spreadsheets), which are stored on a collaborating institution's computer network. This information comprises clinical health information data and identifiers.
- 1a. Clinical health information data are the collection of facts and opinions about an individual's health and wellbeing. Treatment details are an example of clinical health information data.
- 1b. Identifiers are the data items, which identify the individual who is described within a patient record. A patient's name is an example of an identifier.
2. The patient information is copied into replica data sources, which are stored on the collaborating institution's Local Research Repository (LRR), on a nightly basis or frequency agreed by the collaborating institution.
3. A limited set of identifiers from each new patient record are sent from the replica data sources to BioGrid Australia's Linkage Key Federator (LKF) via a secure encrypted Virtual Private Network (VPN) connection.
4. The Linkage Key Federator (LKF) forwards the identifiers to BioGrid Australia's Linkage Key server. This server hosts the Unique Subject Identifier (USI) database.
5. The identifiers are compared with the USI database's records to establish whether data about the patient already exists within a BioGrid-linked data source.
If a match is found for a patient's data, the patient has previously been allocated a USI. If no match is found for a patient's data, the patient's set of identifiers and a new USI are written to the USI database.
6. The USIs for the matching and non-matching patients are sent back to the LKF.
7. The USIs are sent back to the LRR via a secure encrypted VPN connection and stored with their associated clinical health information data.

8. Once authorised access via the BioGrid Australia Data Access Application System has been provided to the researcher, they can commence querying the de-identified data they have approval to access.
9. The researcher submits a data query to BioGrid Australia's statistical analysis (SAS) computer via the Internet.
10. The SAS computer forwards the query to the FDI.
11. The FDI requests the specified data from each of the relevant LRRs via a secure encrypted VPN connection.
12. The clinical health information data and USIs from applicable patient records are sent to the FDI via a secure encrypted VPN connection. These data are combined into a temporary table. The table is removed from the FDI upon completion of the query.
13. The SAS computer reads and processes data from the temporary table.
14. The SAS computer presents the results of the query to the researcher.

BioGrid provides alternative matching methodology referred to as exact matching using a cryptographic hashing function when individual identifiers cannot be brought together in one place for comparison.

- ⬆ Highly secure hash generating software is installed at collaborating institution. The hashing algorithm is run at collaborating institution's site on the replica data sources. A unique hash value is created for each set of identifying patient data. No identifying information ever leaves the source site.
- ⬇ Unique hash value from each new patient record is sent from the replica data source to BioGrid Australia's Linkage Key Federator (LKF) via a secure encrypted Virtual Private Network (VPN) connection. No identifying information ever leaves the source site.
- ⦿ The LKF synchronises its matches with the BioGrid Australia's Linkage Key server. This server hosts the Unique Subject Identifier (USI) database.

Operational Report

BioGrid moves!

In February 2022, BioGrid relocated from the Centre for Medical Research in the Royal Melbourne Hospital to Jane Bell House, not far from the hospital in Wreckyn Street, North Melbourne.

This move was part of Royal Melbourne Hospital's realignment of their tenancy spacing and has the benefit of providing increased desk space as BioGrid's team grows.

MRFF grant quoting

During this financial year, we assisted members with eight MRFF grant applications due in February 2022, covering research in the areas of cancer, biobanking, infectious disease and antimicrobial prescribing.

This involved helping the applicants define the data solution that would best enable them to deliver their research requirements and produce a detailed costing for inclusion in the grant application. This is the first time we have been directly involved in helping our members prepare their grant applications in terms of the data solutions. This work has grown out of increased awareness of BioGrid's expertise in designing solutions based on the specific requirements of a project, and we expect this work will grow in future years.

New funding partner for ePAD

The ePad project, which commenced in 2016, received additional funding for 2 years from a new funding partner, Merck Sharp & Dohme (MSD) USA.

This will enable the project to expand into Asia. Initial partner sites are expected to be Singapore, Taiwan, and Korea.

Communications Specialist engaged

Anita Coia was appointed late in the 2021-22 financial year to provide marketing and communications consultancy services to BioGrid.

Anita commenced work on creating digital promotional material and case studies as well as content for the BioGrid website, newsletters and social media. This will ensure members and other stakeholders have current, comprehensive information about BioGrid and the projects we are supporting, as well as provide material that BioGrid can use when speaking with researchers about what BioGrid does and how BioGrid can help address their data problems.

VCCC Alliance Data Driven Research Hub

In January 2022, BioGrid signed a 3-year agreement with the VCCC Alliance for data linkage services to support a Data Driven Research Hub, funded by the Victorian Government.

This collaboration between the VCCC Alliance, the University of Melbourne, hospitals and BioGrid Australia will enable the linking of primary care and hospital data for the first time in Australia.

Conferences

- BioGrid had an abstract accepted about the Australian Rare Cancer Portal for an oral presentation at the eResearch Australasia conference, held virtually on 11-15 October 2021.
- Maureen Turner, BioGrid CEO, was an invited speaker for a panel discussion on "Partnering for Data Access" at the Innovate Health 2021 conference which was held in November 2021.



MRFF grant quoting

During this financial year, we assisted members with eight MRFF grant applications due in February 2022, covering research in the areas of cancer, biobanking, infectious disease and antimicrobial prescribing.

This involved helping the applicants define the data solution that would best enable them to deliver their research requirements and produce a detailed costing for inclusion in the grant application. This is the first time we have been directly involved in helping our members prepare their grant applications in terms of the data solutions. This work has grown out of increased awareness of BioGrid's expertise in designing solutions based on the specific requirements of a project, and we expect this work will grow in future years.

ARC Portal update

The ARC Portal, launched in 2019, is an online referral service that aims to improve outcomes and equity of access to research for Australians diagnosed with a rare cancer, particularly those living in rural, regional and remote areas. The ARC Portal is supported and managed by BioGrid Australia.

By the end of the 2021-22 financial year, the ARC Portal had more than 162 clinicians registered as referrers. These referrers represented every state and territory and included clinicians from regional and metropolitan centres. In addition, over 50 medical specialists from Australia and internationally who are considered to be experts in treating rare cancers have provided expert input into referred cases.

To date the ARC Portal has received referrals for 1143 patients with rare cancers from across Australia. Over two thirds of patients had active disease, with either a new diagnosis (24.5%) or relapsed/progressing disease (48.2%), with the remainder stable (16.4%) or in remission (10.9%). A survey of referrers, presented at the COSA 2021 annual scientific meeting, found that the ARC portal reports impacted patient care in 42% of referrals, either by influencing subsequent choice of treatment, access to subsequent diagnostic or molecular testing, or facilitating enrolment into a clinical trial or research program.

The ARC Portal is working with the REVITILISE network (Regional Victorian Regional Trials Alliance, Linkages, Special Populations, Equity) to provide the online infrastructure which will enable a new regional Victorian multidisciplinary meeting for rare urological tumours. This targeted program will allow patients in rural and regional Victoria with rare or complex cancers access to the same sub-specialist experts as patients able to attend specialist cancer centres. This program will act as a potential pilot program for other remote regions and rare tumour types. Importantly, this will upskill regional cancer specialists who otherwise might not have the opportunity to dial into the specialist cancer centre Multi-Disciplinary Meetings.

Other achievements during the 2021-22 financial year include:

- Implemented remote consent via SMS or e-mail is now available for quick and convenient patient enrolment
- Presented an introduction to the ARC Portal including its role, workflow and function at the 2021 Medical Oncology Group of Australia (MOGA) annual scientific meeting
- Presented a retrospective analysis of the impact of ARC portal reports at the 2021 Clinical Oncology Society of Australia (COSA) annual scientific meeting

The ARC Portal continues to demonstrate its value in ensuring that patients in areas where specialist knowledge and services are difficult to access receive care on par with that available to patients in urban areas.

Find out [more about ARC Portal](#).

Projects

APPRISE Virtual Biobank: Leveraging technology to maximise the value of human biospecimens

Human biospecimens are a highly valuable resource for researchers – but they are expensive to collect and store, and specimen banking is often fragmented and siloed. The Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) Centre for Research Excellence (CRE) recognised the importance of establishing an infectious diseases biobank to help inform emergency responses prior to COVID-19, but progress towards a single national biobank of existing specimens was stymied by issues of governance and data ownership.

The COVID-19 pandemic provided the perfect real-life case study demonstrating the value of timely access to existing specimens and creating a sense of urgency to develop a solution. BioGrid was able to address some of the previous barriers by offering a technical solution that removed the need to create a new, single biobank. Instead, the BioGrid platform leveraged six existing COVID-related biobanks nationally, connecting them virtually under their current governance arrangements but enabling their specimens to become more widely searchable.

APPRISE provided the collaborations and infectious disease expertise for the virtual biobank, and BioGrid developed the technical architecture. The advantage of the BioGrid solution was that the collection and distribution arrangements for individual collections remain unchanged, but researchers can easily use a single website to get an overview of samples available from multiple collections. Data held by individual collections does not “move” or get transferred to a central database; instead, data aggregation for the portal is done whilst maintaining the individual governance and access arrangements associated with each biospecimen collection.

This approach is far more efficient than trying to harmonise disparate collections, and BioGrid’s overarching governance structure and technical platform makes it easier to deal with different jurisdictions and locations, public and private organisations, and varying technical architecture.

A ‘minimum information’ model was developed that ensures the essential information needed to create a harmonised view is available for the virtual portal. This model defines the information required from each collection for searching via the virtual biobank portal. The aggregate data viewed from an online search request is held in temporary memory while the end user is querying the virtual biobank databases and is destroyed once the session ends.

Providing a portal to existing collections also means that when access is required, it can happen quickly. The individual collections are updated in real time without impacting any of the BioGrid infrastructure, and the search results include all current data.

Read more about [BioGrid’s work on APPRISE](#).



National Inpatient Penicillin Allergy Database: improving hospital procedures and national policy on antibiotic prescribing

The National Inpatient Penicillin Allergy Database project commenced this year, examining the issues of penicillin allergy and antibiotic resistance.

Ten percent of the Australian population have a penicillin allergy, but the situation is actually not that straight forward. In fact, about 90% of that group are not truly allergic to penicillin, which means they are at risk of receiving the wrong treatment.

Globally, antibiotic resistance is rising to dangerously high levels, and over-use of antibiotics is a contributing factor.

Having solid data about the current situation regarding the burden of antibiotic allergies, their impact on antibiotic prescribing and modes of antibiotic allergy testing, is key to effective antibiotic use policies and procedures.

The National Antibiotic Allergy Network (NAAN) provides a framework for collaborative health services research in antibiotic allergy and part of this action is the formation of a database for inpatient antibiotic allergy testing, known as the National Inpatient Penicillin Allergy Database.

This database will ultimately provide a platform for informing a standardised assessment and oral challenge (i.e. test dose) procedure, and a method for capturing the resulting data, which can then be used for auditing and improving hospital procedures and national policy. This work will potentially provide vital data to inform the National Allergy Strategy and National Allergy Centre for Excellence (NACE) in the future.

“In addition, the BioGrid relationship presents exciting possibilities in the future to link data from other studies with the National Inpatient Penicillin Allergy database to examine the relationship between penicillin allergy and other health factors” said Professor Jason Trubiano, Director of Infectious Diseases, Austin Health.

The app utilises published clinical assessment tools, such as the Antibiotic Allergy Assessment Tool and PEN-FAST calculator, to provide clinicians with a platform to easily collect penicillin allergy phenotypic data and enable a resultant risk-assessment. The app also allows oral challenge data collection at the point-of-care.

The data collected by the app is not stored locally but is safely transferred via the cloud to a REDCap database securely hosted by BioGrid.

Read more about the [National Inpatient Penicillin Allergy Database](#).

Projects

Learning Health Systems (LHS) and informatics

Harnessing the power of data in health care is a complicated business, but the Centre for Digital Transformation of Health at the University of Melbourne is leveraging real-world data to train health professionals in Learning Health Systems (LHS) and informatics.

Using real-world data, the online course is focused on improving patient outcomes by teaching participants a range of hard and soft skills for using data to build, implement, and evaluate innovative solutions to health challenges.

Building innovative models of care requires learning from data: collect it, 'clean' it, analyse it and then bring that insight to the point of care to improve decision making. Clinicians then need to measure outcomes and keep collecting data to continuously learn how to improve care.

Complementing the data skills is building awareness that innovative solutions require a breadth of different skills and experience reflecting the complexity of real-life treatment environments. This means that the ability to work cooperatively across specialties and disciplines is a key outcome.

The Learning Health System (LHS) approach aims to streamline improvements to individual and population health, by bridging the evidence-to-practice gap. Patients and clinicians can use the framework to build evidence collaboratively and apply it to innovation, quality and safety and to create value in health care.

BioGrid's participation will be essential in ensuring that LHS participants were working with data that was the same as data they would encounter in actual practice; from multiple sources and through timeframes, enabling the tracking of treatment presentations and outcomes.

Without access to these data, the LHS developers would not be able to design a "real-world" case study to teach the applied skills in informatics and data analytics and ensure that it was relevant to the specific Australian healthcare context.

BioGrid's rigorous data governance, privacy and security ensured that all patient data was de-identified but could be linked appropriately and used accurately in analysis across data sources, enabling powerful modelling for the development of innovative solutions.

Read more about the [Learning Health System and Informatics project](#).



BREAST Registry – Real World Evidence to tackle breast cancer

Breast cancer has a devastating impact on our community as it is the most common cancer among women. Breast cancer kills more than 3300 Australians a year and one woman under the age of 40 is expected to die from it each week.

Breast cancer can be classified as early, locally advanced, or metastatic, and is further categorised by receptor status (hormone receptor positive, HER2-positive, or triple negative).

“What’s unique about breast cancer is that it’s not the one disease unlike some other types of cancers,” says Dr Sheau Wen Lok, the Principal Investigator for the BREAST registry. “There are traditionally three distinct subtypes of breast cancer, each with different prognoses and treatment options.”

For this reason, real world evidence about the efficacy of treatments, particularly when considered in the context of patient comorbidities and lifestyle factors, is an important complement to clinical trial data.

The BREAST database, developed by BioGrid, acts as a portal, bringing together three existing, independently approved standalone registries that aim to improve understanding of the treatment and outcomes of breast cancer patients, providing an important resource for researchers and clinicians.

“It’s really helpful to have the BioGrid team providing support at all stages of the development of BREAST and the sub registries,” says Dr Lok.

The three registries within BREAST are TABITHA (Treatment of Advanced Breast Cancer in the HER2 Positive Australian Patient), ARORA (Advanced Hormone Receptor Positive Breast Cancer Registry in Australia), and TRACIE (TRodelvy use in AdvanCed Trlple Negative BrEast Cancer in Australia).

Read more about the [BREAST Registry](#).

Directors' Report



Dr Robert Grenfell

MBBS, MPH, FAFPHM, MAICD

**Director since October 2017,
Chair since September 2018**

Special Health Advisor, CSIRO, (2020 – present)

Director – Health and Biosecurity, CSIRO, (2015 – 2020)

Director, Grenfell Health Consulting (1997 – present)

Director, Maree Stopes Health (2011 – 2016)

Chair, General Practice Victoria (2007 – 2010)

Director, General Practice Victoria (1998 – 2007)

Director – Health and Biosecurity, CSIRO, (2015 – present)



Associate Professor Paul Cooper

BSc, PhD, GradDip Bus, FACHI,
CHIA, GAICD, AFHEA

**Director since August 2018,
Deputy Chair since September 2018**

Director, Longboardfella Consulting, (2020 – present)

Director, Calliston Consultants Pty Ltd (2016 – 2020)

Member, Human Research Ethics Committee, St Vincent's Healthcare (2019 – present)

Digital Content Curator, Australasian Institute of Digital Health, Precision Health Community of Practice (2021 – present)

Digital Content Curator, Australasian Institute of Digital Health, Victorian Branch (2021 – present)

Member, WEHI Advocacy and Support Committee (2017 – present)

Associate Professor, Health Informatics Management, Faculty Health, School of Medicine, Deakin University (2016 – present)

Secretary, Australasian Institute of Digital Health, Precision Health Community of Practice (2017 – 2021)

Director, Victorian Continence Resource Centre (2015 – 2020)

Secretary, Australasian Institute of Digital Health, Victorian Branch (2017 – 2019)

Director, Digital Health, Department of Health and Human Services, Victorian Government (2017 – 2018)



Mr Christopher Arnold

B Comm, MBA, FCPA, FAICD, AFACHSM

Director since March 2014

Principal, Hodgson Associates, (2010 – present)
Director, Melbourne Anglican Foundation (2021 – present)
Director, Australian World Orchestra (2019 – present)
Director, Melba Opera Trust (2017 – 2020)
Director, Skin & Cancer Foundation Inc (2009 – 2019)
Chair, Human Variome Project International Ltd (2014 – 2017)
Director, Human Variome Project International Ltd (2008 – 2017)
Chair, Telediagnostics Pty Ltd (2010 – 2016)
Director, Philanthropy Australia (2003 – 2009)
Director, Australian Communities Foundation (1999 – 2007)



Mr David Polonsky

B Bus, CA, TIA, MAICD

Director since January 2015

Director, DRP Consulting Pty Ltd, (1996 – present)
Director, Moore Stephens (Vic) Pty Ltd (formerly Nexia Melbourne Pty Ltd), (2011 – 2017)
Director, Private Ancillary Funds (various to present)
Director Spirit of Australia Foundation (2018 – present)

Directors' Report



Professor Karin Verspoor

BA, MSc, PhD, GCUT

Director since August 2016

Executive Dean, School of Computing Technologies, RMIT University, (2021 - present)

Honorary Professor, School of Computing and Information Systems, University of Melbourne, (2021 - present)

Fellow, Australasian Institute for Digital Health (2020-present)

Deputy Director, ARC Industrial Transformation Training Centre in Cognitive Computing for Medical Technologies (2018 - present)

Professor, School of Computing and Information Systems, University of Melbourne (2017 - 2021)

Director of Health Technologies, Melbourne School of Engineering, University of Melbourne (2020 - 2021)

Deputy Director, Centre for Digital Transformation of Health, University of Melbourne (2019 - 2021)

Fellow, Centre for Business Analytics, Melbourne Business School (2015 - 2020)

Deputy Head of School (Research), School of Computing and Information Systems, University of Melbourne (2019 - 2020)

Deputy Head of Department (Operations), Department of Computing and Information Systems, University of Melbourne (2015 - 2019)

Deputy Director, Health and Biomedical Informatics Centre, University of Melbourne (2014 - 2019)

Associate Professor, School of Computing and Information Systems, University of Melbourne (2014 - 2016)

President, Australasian Language Technology Association (ALTA) (2013 - 2014)

Scientific Director, Health and Life Sciences, National ICT Australia (NICTA) (2012 - 2014)



Dr James Dromey

BSc PhD

Director from August 2018 to June 2022

Chief Innovation Officer, Murdoch Children's Research Institute, (May 2021 - present)

Chief Operating Officer, Murdoch Children's Research Institute (2016 - 2021)

Director, Raising Children Network, (2021 - present)

Director, GI Therapies, September (2012 - present)



Professor Clare Scott

MBBS, PhD, FRACP, FAHMS

Director since March 2020

Joint Division Head, Clinical Translation, Walter and Eliza Hall Institute of Medical Research, (2019 - present)

Head, Ovarian and Rare Cancers Laboratory, Walter and Eliza Hall Institute of Medical Research, (2010 - present)

Consultant Medical Oncologist, Peter MacCallum Cancer Centre (2016 - present), Royal Women's Hospital (2010 - present), Royal Melbourne

Hospital (2006 - present)

Chair Elect, Australia New Zealand Gynaecology Oncology Group (ANZGOG) (2021 - present)

Member, Scientific Advisory Board Oncology One (2021 - present)

Director, Cancer Trials Australia (2021 - present)

Chair, International Rare Cancer Initiative (IRCI) Board (2020 - present)

Chair, Gynaecological Cancer, University of Melbourne (2018 - present)

Chair, Gynaecologic Cancer InterGroup (GCIG) Rare Tumour Committee (2016 - present)

Chair, Clinical Oncology Society of Australia (COSA) Rare Cancers Group (2015 - present)

Director, Australia New Zealand Gynaecology Oncology Group (ANZGOG) (2014 - present)

Member, International Rare Cancer Initiative (IRCI) Board (2015 - 2020)

Directors' Report

Meetings attended

The following outlines meetings held and attended by each of the Directors and Member Representatives in 2021-22.

Director	Board of Directors		Finance, Audit & Risk Committee	
	Held	Attended	Held	Attended
Chris Arnold	6	6	6	6
Paul Cooper	6	5		
James Dromey	6	4		
Rob Grenfell	6	6		
David Polonsky	6	6	6	6
Clare Scott	6	6		
Karin Verspoor	6	6		

Member Representatives on Committees

Glenn Murphy (Melbourne Health)			6	6
------------------------------------	--	--	---	---

Contribution in winding up

The entity is incorporated under the Corporations Act 2001 and is a company limited by guarantee. As such, no shares are issued or held by directors. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the entity. At 30 June 2022 the amount the members of the Company are liable to contribute if the Company wound up is \$350 (the number of members was 35).

Principal activities

The principal activities of the Company are data sharing that advances health research by linking privacy-protected and ethically approved clinical, imaging, biospecimen and genetic data among a wide network of health collaborators. During the year there was no significant change in the nature of those activities.

Company's objectives

The company's objectives are to:

- Facilitate internationally competitive medical research into the causes of ill health and disease;
- Provide an ethically approved privacy-protected service to connect data sources;
- Invest in technology development to ensure ongoing alignment with leading technology that supports privacy-protected data connection; and
- Be sustainable in order to fulfill the company's vision and mission and to service the needs of its' members.

To achieve these objectives, the Company:

- Supported major research program initiatives by providing data linkage and data management services for state and federal funded cancer research projects;
- Worked with key stakeholders in the health sector to facilitate major research projects in Victoria and Australia;
- Provided ongoing training and support for quality specialist staff committed to providing a technology platform that supports medical research through privacy-protected data connection; and
- Implemented the redeveloped business development model for members and industry to support the long-term viability of the company.

Key performance measures

The company measures its own performance through the use of both quantitative and qualitative benchmarks. The benchmarks are used by the directors to assess whether the company's short-term and long-term objectives are being achieved.

	2022		2021	
	Actual	Benchmark	Actual	Benchmark
Total Number of Members/Collaborators	42*	43	42*	43
Current Institution Ethics Approvals	39	40	38	40
Approved Active Research Projects	102**	125	119	140
Journal Publications to Date	325	315	297	295

*At 30 June 2022 there are 35 member and 7 non-member collaborator institutions, a total of 42 BioGrid Australia collaborators.

**Whilst the number of research projects are less, many are larger projects with significantly more data linked per project

Dividends

The Company Constitution forbids the payment or distribution of any profits, income or assets to the members.

Directors' Remuneration

The directors did not receive remuneration from the company with the exception of expenses relating to their director role.

Indemnification of officers and auditors

During the year the Company paid a premium in respect of a contract insuring the directors of the Company, the Company secretary and all executive officers of the Company and of any related body corporate against a liability incurred as such a director, secretary or executive officer to the extent permitted by the Corporations Act 2001. The Company has not otherwise, during or since the year, indemnified or agreed to indemnify an officer or auditor of the Company or of any related body corporate against a liability incurred as such an officer or auditor.

Critical accounting estimates and judgements

The company recorded a deficit of \$92,248 for the year ended 30 June 2022 (2021: \$232,453 deficit) and has negative net assets of \$60,700 at 30 June 2022.

The Directors are pleased to note the substantial increase in turnover resulting from an increased level of enquiry and conversion of tenders to contractual arrangements over the last year. The increased turnover did not result in an immediate return to profit as the first six months of the financial year were impacted by ongoing issues associated with the COVID-19 outbreak. The Directors and senior management team have continued to work on the development of the business and now project a further and substantial increase in turnover and a return to profitability being budgeted for the year ending 30 June 2023 and the following year. The new enquiries reflect the improved awareness of the Company's abilities and offerings, and the interests of new researchers and customers for the unique and comprehensive services being provided, which auger well for the future of the Company.

The Directors advise that the Company has invested over \$80,000 to date in developing and modernizing the Company's infrastructure to a nationally accredited secure digital research environment and curated data service platform. This development is being driven to satisfy customer requirements and expectations and will result in future profitability and success of the Company. The investment of funds expended to date is required to be expensed in accordance with relevant Australian Accounting Standards. The Company would have recorded a positive net equity position at 30 June 2022 if these costs were able to be capitalized and depreciated over the effective life of the new platform. The Directors are seeking the ongoing support of members and customers to allow the Company to progress and realise these critical strategic objectives.

The Directors continue to work closely with key stakeholders who have and continue to show their support for the Company and its future operations as detailed in the Company's strategic plan.

The Directors are pleased to report that the governance and business development initiatives continuing to be undertaken during the 2023 financial year has allowed the Company to continue to operate with a positive net cash flow position which has allowed the Company to pay its debts as and when they fall due.

The Company remains the only collaboration network in Australia with the legal and ethical framework to enable the sharing of real-time health and medical data for research. Accordingly, it is well positioned to take advantage of opportunities as they arise nationally and internationally.

Having considered the above factors, the Directors have concluded that there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due. Should the Company be unable to continue as a going concern, it may be appropriate to realise its assets and discharge its liabilities at amounts different to those stated in the financial report.

Events subsequent to balance date

No matters or circumstances have arisen since the end of the financial year which significantly affected, or may significantly affect, the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

Likely developments in the operations of the Company, and the expected results of those operations in future financial years, have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the Company.

Auditor's Independence Declaration

The lead auditor's independence declaration for the year ended 30 June 2022 has been received and can be found on page 22 of this report.

Signed in accordance with a resolution of the Board of Directors.

On behalf of the Directors



Rob Grenfell, Director

Melbourne, 18 October 2022



David Polonsky, Director

BioGrid Australia Limited
31 136 185 647

Auditor's Independence Declaration

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2022 there have been:

- a) no contraventions of the auditor independence requirements as set out in Section 60.40 of the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- b) no contraventions of any applicable code of professional conduct in relation to the audit.



Saward Dawson



Jeffrey Tulk
Partner

Blackburn, Victoria 3130
Dated: 3 November 2022

20 Albert St, Blackburn VIC 3130
T +61 3 9894 2500 F +61 3 9894 1622
contact@sawarddawson.com.au
sawarddawson.com.au



Liability limited by a scheme approved under Professional Standards Legislation

Financial Report

Statement of Income and Expenditure and Other Comprehensive Income For the Year Ended 30 June 2022

	Note	2022 \$	2021 \$
Revenue	2	2,677,496	2,351,154
Consultant expenses	3	(2,439,533)	(2,273,302)
License fees		(146,970)	(139,397)
Operational Expenses		(68,206)	(71,531)
Professional fees		(64,635)	(48,099)
Depreciation and amortisation		(46,464)	(48,432)
Bank charges		(201)	(473)
Other expenses		(3,914)	(2,373)
Deficit for the year		(92,427)	(232,453)

Statement of Financial Position

As at 30 June 2022

	Note	2022 \$	2021 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	4	34,778	143,134
Trade and other receivables	5	255,198	290,243
Other assets	6	7,477	94,237
TOTAL CURRENT ASSETS		297,453	527,614
NON-CURRENT ASSETS			
Property, plant and equipment	7	23,545	47,272
Intangible assets	8	153,842	140,934
TOTAL NON-CURRENT ASSETS		177,387	188,206
TOTAL ASSETS		474,840	715,820
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	9	311,773	462,381
Other liabilities	10	223,767	221,712
TOTAL CURRENT LIABILITIES		535,540	684,093
TOTAL LIABILITIES		535,540	684,093
NET ASSETS		(60,700)	31,727
EQUITY			
Accumulated surpluses		(60,700)	31,727
TOTAL EQUITY		(60,700)	31,727

Statement of Changes in Equity

For the Year Ended 30 June 2022

2022	Accumulated Surpluses \$	Total \$
Balance at 1 July 2021	31,727	31,727
Deficit for the year	(92,427)	(92,427)
Balance at 30 June 2022	(60,700)	(60,700)

2021	Accumulated Surpluses \$	Total \$
Balance at 1 July 2020	264,180	264,180
Deficit for the year	(232,453)	(232,453)
Balance at 30 June 2021	31,727	31,727

Statement of Cash Flows

For the Year Ended 30 June 2022

	Note	2022 \$	2021 \$
CASH FROM OPERATING ACTIVITIES:			
- Receipts from customers		2,985,066	2,375,305
- Payments to suppliers and employees		(3,057,776)	(2,642,335)
- Interest received		-	15
Net cash provided by (used in) operating activities	11	(72,710)	(267,015)
CASH FLOWS FROM INVESTING ACTIVITIES:			
- Acquisition of property, plant and equipment		-	(2,865)
- Payment for intangible asset		(35,646)	(28,884)
Net cash used by investing activities		(35,646)	(31,749)
CASH FLOWS FROM OTHER ACTIVITIES:			
Net cash increase (decreases) in cash and cash equivalents		(108,356)	(298,764)
Cash and cash equivalents at beginning of year		143,134	441,898
Cash and cash equivalents at end of financial year	4	34,778	143,134

Notes to the Financial Statements

For the Year Ended 30 June 2022

Note 1 Accounting policies

(a) Financial Reporting Framework

BioGrid Australia Limited is a Company limited by guarantee, incorporated and domiciled in Australia. The directors have prepared the financial reports on the basis that the company is a non-reporting entity because there are no users who are dependent on its general purpose financial reports. These financial reports are therefore special purpose financial reports that have been prepared in order to meet the requirements of the *Australian Charities and Not-for-profits Commission Act 2012*. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under the *Australian Charities and Not-for-profits Commission Act 2012* and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with those of previous years unless stated otherwise.

(b) Statement of Compliance

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under *Australian Charities and Not-for-profits Commission Act 2012*, the basis of accounting specified by all Australian Accounting Standards and Interpretations, and the disclosure requirements of Accounting Standards AASB 101: *Presentation of Financial Statements*, AASB 107: *Cash Flow Statements*, AASB 108: *Accounting Policies, Changes in Accounting Estimates and Errors* and AASB 1054: *Australian Additional Disclosures*.

The company has concluded that the requirements set out in AASB 10 and AASB 128 are not applicable as the initial assessment on its interests in other entities indicates that it does not have any subsidiaries, associates or joint ventures.

The company complies with measurement and recognition of all Australian accounting standards except AASB 16: *Leases*

(c) Basis of preparation

The financial reports, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs unless otherwise stated in notes. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The amounts presented in the financial statements have been rounded to the nearest dollar.

(d) Revenue

Operating Grants, Donations and Bequests

When the company receives operating grant revenue, donations or bequests, it assesses whether the contract is enforceable and has sufficiently specific performance obligations in accordance with AASB 15.

When both these conditions are satisfied, the company:

- identifies each performance obligation relating to the grant;
- recognises a contract liability for its obligations under the agreement; and
- recognises revenue as it satisfies its performance obligations.

Where the contract is not enforceable or does not have sufficiently specific performance obligations, the company:

- recognises the asset received in accordance with the recognition requirements of other applicable accounting standards (for example AASB 9, AASB 16, AASB 116 and AASB 138);
- recognises related amounts (being contributions by owners, lease liability, financial instruments, provisions, revenue or contract liability arising from a contract with a customer); and
- recognises income immediately in profit or loss as the difference between the initial carrying amount of the asset and the related amount.

If a contract liability is recognised as a related amount above, the company recognises income in profit or loss when or as it satisfies its obligations under the contract.

Donations and bequests without enforceable contract are recognised as revenue when received. Revenue from the rendering of a service is recognised upon the delivery of the service to the customer.

Interest income is recognised using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument.

All revenue is stated net of the amount of goods and services tax (GST).

(e) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities in the statement of financial position.

(f) Leases

Lease payments are charged as expenses on a straight-line basis over the life of the lease term.

(g) Trade and other receivables

Trade receivables include outstanding funds invoiced to customers for membership fees and completed projects or milestones. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets.

(h) Plant and equipment

Plant and equipment are measured on the cost basis less depreciation and impairment losses. Cost includes expenditure that is directly attributable to the asset.

Depreciation

The depreciable amount of all plant and equipment is depreciated on a straight-line basis over the asset's useful life to BioGrid Australia Limited commencing from the time the asset is held ready for use.

Note 1 Accounting policies continued

(i) Intangibles

Amortisation

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, from the date that they are available for use.

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Software

Software has a finite life and is carried at cost less any accumulated amortisation and impairment losses. It has an estimated useful life of between three and five years.

(j) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

(k) Income taxes

No current or deferred income tax assets or liabilities have been raised by the company as it is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*. The company is a registered charity under the Australian Charities and Not-for-profits Commission.

(l) Trade and other payables

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(m) Going concern

The company recorded a deficit of \$92,427 for the year ended 30 June 2022 (2021: \$232,453 deficit) and has negative net assets of \$60,700 at 30 June 2022.

The Directors are pleased to note the substantial increase in turnover resulting from an increased level of enquiry and conversion of tenders to contractual arrangements over the last year. The increased turnover did not result in an immediate return to profit as the first six months of the financial year were impacted by ongoing issues associated with the COVID 19 outbreak. The Directors and senior management team have continued to work on the development of the business and now project a further and substantial increase in turnover and a return to profitability being budgeted for the year ending 30 June 2023 and the following year. The new enquiries reflect the improved awareness of the Company's abilities and offerings, and the interests of new researchers and customers for the unique and comprehensive services being provided, which auger well for the future of the Company.

The Directors advise that the Company has invested over \$80,000 to date in developing and modernizing the Company's infrastructure to a nationally accredited secure digital research environment and curated data service platform. This development is being driven to satisfy customer requirements and expectations and will result in future profitability and success of the Company. The investment of funds expended to date is required to be expensed in accordance with relevant Australian Accounting Standards. The Company would have recorded a positive net equity position at 30 June 2022 if these costs were able to be capitalized and depreciated over the effective life of the new platform. The Directors are seeking the ongoing support of members and customers to allow the Company to progress and realise these critical strategic objectives.

The Directors continue to work closely with key stakeholders who have and continue to show their support for the Company and its future operations as detailed in the Company's strategic plan.

The Directors are pleased to report that the governance and business development initiatives continuing to be undertaken during the 2023 financial year has allowed the Company to continue to operate with a positive net cash flow position which has allowed the Company to pay its debts as and when they fall due.

The Company remains the only collaboration network in Australia with the legal and ethical framework to enable the sharing of real time health and medical data for research. Accordingly, it is well positioned to take advantage of opportunities as they arise nationally and internationally.

Having considered the above factors, the Directors have concluded that there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due. Should the Company be unable to continue as a going concern, it may be appropriate to realise its assets and discharge its liabilities at amounts different to those stated in the financial report. The directors note the difficult trading and operating conditions since the COVID 19 outbreak in February 2020, but are now being encouraged by the increased level of enquiry which also reflects the interests of new researchers and customers for the unique and comprehensive services being provided by the Company.

	2022 \$	2021 \$
Note 2 Revenue		
Operating revenue		
– Commercial-led projects	664,765	411,767
– Member subscriptions	468,375	479,310
– Investigator-led projects	255,717	318,050
– Researcher user fees	–	35,000
– Grants	1,281,536	1,058,402
– Interest received	–	15
– Other income	7,103	48,610
Total Revenue	2,677,496	2,351,154
Note 3 Consultant expenses		
Consultant expenses include payments to Melbourne Health who provide staff contract and payroll services to BioGrid.		
Note 4 Cash and cash equivalents		
Cash at bank	34,778	143,134
	34,778	143,134
Note 5 Trade and other receivables		
CURRENT		
Accounts receivable	247,439	290,243
GST receivable	7,759	–
	255,198	290,243
Note 6 Other assets		
CURRENT		
Prepayments	7,477	94,237
	7,477	94,237
Note 7 Plant and equipment		
Plant and equipment		
At cost	127,022	134,585
Less accumulated depreciation	(103,477)	(87,313)
Total plant and equipment	23,545	47,272
Note 8 Intangible assets		
Computer software		
At cost	186,100	150,454
Less accumulated amortisation	(52,000)	(43,708)
Net carrying value	134,100	106,746
Website Development		
At cost	68,023	68,023
Less accumulated amortisation	(48,281)	(33,835)
Net carrying value	19,742	34,188
Total Intangibles	153,842	140,934

	2022 \$	2021 \$
Note 9 Trade and other payables		
CURRENT		
Trade payables	220,554	309,674
Accruals	91,219	145,014
GST payable	–	7,693
	<u>311,773</u>	<u>462,381</u>

Note 10 Other Liabilities

CURRENT		
Industry project income received in advance	203,500	110,213
Investigator income received in advance	20,267	20,267
Grant income received in advance	–	91,232
	<u>223,767</u>	<u>221,712</u>

Note 11 Cash flow information

Reconciliation of cash flow from operations with net current year deficit		
Net result for the year	(92,427)	(232,453)
Cash flows excluded from surplus attributable to operating activities		
– Depreciation and amortisation	46,465	48,432
Changes in assets and liabilities		
– (Increase)/decrease in trade receivables	35,045	(197,665)
– (Increase)/decrease in other assets	86,760	324
– (Increase)/decrease in trade payables	(150,608)	115,750
– Increase/(decrease) in other liabilities	2,055	(1,403)
	<u>(72,710)</u>	<u>(267,015)</u>

Note 12 Events after the end of the Reporting Period

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in future financial years.

Note 13 Company Details

The registered office of the Company is:

BioGrid Australia Limited
Level 8, CMR Building
Royal Melbourne Hospital
300 Grattan St, Parkville Victoria 3052

BioGrid Australia Limited

31 136 185 647

Directors' Declaration

The Directors have determined that the Company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

The Directors of the Company declare that:

- (a) the financial report and notes are prepared in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, and;
- (b) In the Directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with subsection 60.15 (2) of the *Australian Charities and Not-for-profits Commission Regulation 2013*.



Robert Grenfell
Director



David Polonsky
Director

Dated: 18 October 2022

Independent Audit Report to the members of BioGrid Australia Limited

Opinion

We have audited the financial report of BioGrid Australia Limited (the Company), which comprises the statement of financial position as at 30 June 2022, the statement of income and expenditure and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of the Company is in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- i. giving a true and fair view of the Company's financial position as at 30 June 2022 and of its financial performance for the year ended; and

- ii. complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

20 Albert St, Blackburn VIC 3130
T +61 3 9894 2500 F +61 3 9894 1622
contact@sawarddawson.com.au
sawarddawson.com.au



 **Russell Bedford**
taking you further
Member of Russell Bedford International

Liability limited by a scheme approved under Professional Standards Legislation

Emphasis of Matter

Material Uncertainty Related to Going Concern

We draw attention to Note 1(m) in the financial report, which indicates that the company incurred a net deficit of \$92,427 during the year ended 30 June 2022 and, as of that date, the company's net assets was in a net deficit position of \$60,700. As stated in Note 1(m), these events and conditions indicate that a material uncertainty exists that may cast doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Basis of Accounting

Without modifying our opinion, we draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report is prepared to assist BioGrid Australia Limited to meet the requirements of the *Australian Charities and Not-for-profits Commission Act 2012*. As a result, the financial report may not be suitable for another purpose.

Responsibilities of Directors for the Financial Report

The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Saward Dawson



Jeffrey Tulk
Partner

Blackburn, Victoria
Dated: 3 November 2022

20 Albert St, Blackburn VIC 3130
T +61 3 9894 2500 F +61 3 9894 1622
contact@sawarddawson.com.au
sawarddawson.com.au



Liability limited by a scheme approved under Professional Standards Legislation

BioGrid Australia

ABN: 31 136 185 647

Level 3, Jane Bell House
Royal Melbourne Hospital
10 Wreckyn Street
North Melbourne
VIC 3051 Australia

T +61 (0)3 9342 2690

F +61 (0)3 9342 8548

enquiries@biogrid.org.au
www.biogrid.org.au

Design: Taylor & Grace

